CA3049624A1 - Probiotic compositions and uses thereof - Google Patents

Probiotic compositions and uses thereof Download PDF

Info

Publication number
CA3049624A1
CA3049624A1 CA3049624A CA3049624A CA3049624A1 CA 3049624 A1 CA3049624 A1 CA 3049624A1 CA 3049624 A CA3049624 A CA 3049624A CA 3049624 A CA3049624 A CA 3049624A CA 3049624 A1 CA3049624 A1 CA 3049624A1
Authority
CA
Canada
Prior art keywords
cells
lactobacillus
mean
probiotic
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3049624A
Other languages
English (en)
French (fr)
Inventor
Daniel AGARDH
Irini Lazou Ahren
Lars Niklas Larsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probi AB
Original Assignee
Probi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by Probi AB filed Critical Probi AB
Publication of CA3049624A1 publication Critical patent/CA3049624A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3049624A 2017-01-12 2018-01-12 Probiotic compositions and uses thereof Pending CA3049624A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GB1700542.2 2017-01-12
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof
GB1709731.2 2017-06-19
PCT/EP2018/050789 WO2018130667A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA3049624A1 true CA3049624A1 (en) 2018-07-19

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049624A Pending CA3049624A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Country Status (14)

Country Link
US (1) US11166993B2 (https=)
EP (1) EP3568144B1 (https=)
JP (1) JP7089523B2 (https=)
KR (1) KR102500496B1 (https=)
CN (1) CN110177561B (https=)
AU (1) AU2018207946B2 (https=)
BR (1) BR112019014418A2 (https=)
CA (1) CA3049624A1 (https=)
CL (1) CL2019001938A1 (https=)
MX (1) MX2019008292A (https=)
MY (1) MY195253A (https=)
PH (1) PH12019501629A1 (https=)
RU (1) RU2763311C2 (https=)
WO (1) WO2018130667A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112584848A (zh) * 2018-06-18 2021-03-30 普罗比公司 益生菌组合物及其用途
IT201900014550A1 (it) * 2019-08-09 2021-02-09 Abiogen Pharma Spa Uso di colecalciferolo come agente attivo nel trattamento della celiachia
CN116869141A (zh) * 2022-05-05 2023-10-13 内蒙古一康健康发展有限责任公司 一种具有保健功能的益生菌复合物及其制备方法
KR102845919B1 (ko) * 2023-02-28 2025-08-14 주식회사 피엘비앤비 장내 유해세균의 성장 억제 성능이 우수한 한국인 모유 유래 락티카제이바실러스 파라카제이 pl1536 및 이를 유효성분으로 포함하는 기능성식품 조성물
CN119279210A (zh) * 2024-12-16 2025-01-10 山东健源生物科技有限公司 一种复合益生菌发酵含药食同源物质的多谷物后生元制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
ZA200802934B (en) * 2005-10-06 2009-09-30 Probi Ab Use of lactobacillus for treatment of virus infections
AU2006297896B2 (en) 2005-10-06 2011-12-08 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
DK1996696T3 (en) 2006-03-17 2017-03-20 Probi Ab Thermostable lactobacillus strains
WO2007108763A1 (en) 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
CN102438643B (zh) 2008-11-30 2015-07-01 免疫桑特公司 用于治疗乳糜泻的组合物和方法
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
ES3010649T3 (en) 2012-06-18 2025-04-04 Heinz Co Brands H J Llc Gluten-related disorders
US10245290B2 (en) * 2013-04-03 2019-04-02 Probi Ab Probiotic strains for use in treatment or prevention of osteoporosis
ES2764210T3 (es) * 2014-11-25 2020-06-02 Dsm Ip Assets Bv Lactobacillus para usar como probiótico

Also Published As

Publication number Publication date
RU2763311C2 (ru) 2021-12-28
US20190358275A1 (en) 2019-11-28
WO2018130667A1 (en) 2018-07-19
EP3568144C0 (en) 2024-05-08
CL2019001938A1 (es) 2019-09-27
AU2018207946A1 (en) 2019-07-25
AU2018207946B2 (en) 2024-07-18
RU2019121145A3 (https=) 2021-04-26
EP3568144A1 (en) 2019-11-20
RU2019121145A (ru) 2021-02-12
JP7089523B2 (ja) 2022-06-22
US11166993B2 (en) 2021-11-09
JP2020513780A (ja) 2020-05-21
CN110177561B (zh) 2023-09-12
EP3568144B1 (en) 2024-05-08
KR20190104568A (ko) 2019-09-10
BR112019014418A2 (pt) 2020-04-14
MX2019008292A (es) 2019-09-16
MY195253A (en) 2023-01-11
PH12019501629A1 (en) 2020-06-01
CN110177561A (zh) 2019-08-27
KR102500496B1 (ko) 2023-02-16

Similar Documents

Publication Publication Date Title
AU2018207946B2 (en) Probiotic compositions and uses thereof
Miyazawa et al. Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study
Cook et al. Circulating gluten-specific FOXP3+ CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease
Hornsby et al. Vitamin D supplementation during pregnancy: effect on the neonatal immune system in a randomized controlled trial
DK1951272T3 (en) Use of lactobacillus for treatment of virus infections
Hirose et al. Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults
EP3539548B1 (en) Composition for inducing proliferation or accumulation of regulatory cells
Palma et al. Interplay between human leukocyte antigen genes and the microbial colonization process of the newborn intestine.
Hardy et al. Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease
WO2016209806A1 (en) Induction of lamina propria regulatory t cells
Kim et al. Identification of atopic dermatitis phenotypes with good responses to probiotics (Lactobacillus plantarum CJLP133) in children
Sredkova et al. Prebiotics can change immunomodulatory properties of probiotics
US11590181B2 (en) Serpin production
WO2015004270A1 (en) Diagnosis, prognosis and treatment of inflammatory bowel diseases
Rossi Biotechnological Strategies for the Treatment of Gluten Intolerance
Huang et al. Propionic fermentation by the probiotic Propionibacterium freudenreichii to functionalize whey
Enomoto et al. Oral administration of Lactobacillus plantarum NRIC0380 suppresses IgE production and induces CD4+ CD25+ Foxp3+ cells in vivo
Nehra et al. Celiac disease and its therapy: current approaches and new advances
Motkowski et al. Peripheral blood T lymphocyte subsets in children with congenital asplenia
Zhao Immune responses alter in heterogeneous nuclear ribonucleoprotein I knockout mice with medium protein diet or probiotic intervention
Berryman Genetic Risk for Autoimmunity Is Associated With Potential for Dysbiosis and Inflammation Early in Life
Linker Aus dem Lehrstuhl für Neurologie Prof. Dr. med. Ralf Linker der Fakultät für Medizin der Universität Regensburg
HK40075389B (en) Composition for inducing proliferation or accumulation of regulatory t cells
Sánchez et al. Effect of maize prolamins on peripheral blood mononuclear cells from celiac disease patients
Hungerford Coeliac disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230106

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241112

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241223

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241223

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250109

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250211

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251015

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251210

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106